Literature DB >> 8510267

p53 gene alterations in human prostate carcinoma.

P J Effert1, R H McCoy, P J Walther, E T Liu.   

Abstract

Alterations of the p53 gene are among the most frequent genetic lesions in a variety of human malignancies. Their role in prostate cancer is, however, unclear. We have analyzed 10 primary and two metastatic human prostate carcinomas as well as 3 prostate cancer cell lines for mutations of the p53-gene. Using single strand conformational polymorphism analysis (SSCP) and direct sequencing of the polymerase chain reaction (PCR) products, p53 mutations were detected in 1 of 10 primary prostate cancers. By contrast, 1 of 2 metastatic tumors and all 3 prostate cancer cell lines (derived from metastases) were found to contain a mutant p53 gene. Thus, our data suggest that alterations of the p53 gene at the mutational "hot spots" appear to occur infrequently in primary human prostate cancer, but may emerge in later stages of tumor progression. Furthermore, we confirm that loss of heterozygosity at a locus telomeric to p53, but not including p53, is associated with metastatic progression in 1 case.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510267     DOI: 10.1016/s0022-5347(17)35458-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  P53 expression in stage I squamous cell lung cancer.

Authors:  J Moldvay; J Strausz; M Egerváry; L Agócs; J Bocsi; Z Schaff
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 2.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Authors:  Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

Review 4.  Prostate cancer: Re-focusing on androgen receptor signaling.

Authors:  Maria Nieto; Stephen Finn; Massimo Loda; William C Hahn
Journal:  Int J Biochem Cell Biol       Date:  2007-01-20       Impact factor: 5.085

5.  Cys-141 glutathionylation of human p53: Studies using specific polyclonal antibodies in cancer samples and cell lines.

Authors:  Mohd A Yusuf; Trinette Chuang; G Jayarama Bhat; Kalkunte S Srivenugopal
Journal:  Free Radic Biol Med       Date:  2010-06-25       Impact factor: 7.376

Review 6.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

8.  Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas.

Authors:  R H Edwards; N Raab-Traub
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

10.  A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.

Authors:  J Kim; M Roh; I Doubinskaia; G N Algarroba; I-E A Eltoum; S A Abdulkadir
Journal:  Oncogene       Date:  2011-06-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.